Early measles vaccination in bone marrow transplant recipients

Bone Marrow Transplantation

Volumn 35, Issue 8, 2005, Pages 787-791

  Machado, C M ^a   de Souza, V A U F ^a   Sumita, L M ^a   da Rocha, I F ^a   Dulley, F L ^a   Pannuti, C S ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Early vaccination; Long term immunity; Measles vaccine; Safety

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MEASLES MUMPS RUBELLA VACCINE; MEASLES VACCINE; MELPHALAN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ANTIBODY TITER; APLASTIC ANEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC; FEVER; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HODGKIN DISEASE; HUMAN; MAJOR CLINICAL STUDY; MEASLES; MEASLES VACCINATION; MYALGIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECIPIENT; SEROCONVERSION; VIRUS IMMUNITY; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; AGED; BONE MARROW TRANSPLANTATION; CHILD; DISEASE OUTBREAKS; HUMANS; IMMUNIZATION SCHEDULE; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; MEASLES; MEASLES VACCINE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; PROSPECTIVE STUDIES; TIME FACTORS; TRANSPLANTATION CONDITIONING;

EID: 17144417945     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704878     Document Type: Article

References (14)

1. Ljungman P, Fridell E, Lonnqvist B et al. Efficacy and safety of vaccination of marrow transplant recipients with live attenuated measles, mumps and rubella vaccine. J Infect Dis 1989; 159: 610-615.
2. Ljungman P, Lewensohn-Fuchs I, Hammarstrom V et al. Long-term immunity to measles, mumps, and rubella after allogeneic bone marrow transplantation. Blood 1994; 84: 657-663.
3. Machado CM, Gonçalves FB, Pannuti CS et al. Measles in bone marrow transplant recipients during an outbreak in São Paulo, Brazil. Blood 2002; 99: 83-87.
4. Ljungman P, Aschan J, Barkholt L et al. Measles immunity after allogeneic stem cell transplantation; influence of donor type, graft type, intensity of conditioning, and graft-versus host disease. Bone Marrow Transplant 2004; 34: 589-593.
5. Ljungman P, Cordonnier C, Bock R et al. Immunizations after bone marrow transplantation: results of a European survey and recommendations from the infectious diseases working party of the European group for Blood and Marrow Transplantation. Bone Marrow Transplant 1995; 15: 455-460.
6. Somani J, Larson RA. Reimmunization after allogeneic bone marrow transplantation. Am J Med 1995; 98: 389-398.
7. King SM, Saunders EF, Petric M, Gold R. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients. Bone Marrow Transplant 1996; 17: 633-636.
8. Singhal S, Mehta J. Reimmunization after blood or marrow stem cell transplantation. Bone Marrow Transplant 1999; 23: 637-646.
9. Dykewicz CA, Jaffe HW, Kaplan JE. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Morb Mortal Wkly Rep 2000; 49 (RR-10): 1-128.
10. Souza VAUF, Pannuti CS, Sumita LM, Andrade Jr HF. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines. J Med Virol 1997; 52: 275-279.
11. Angel JB, Udem SA, Snydman DR. Measles pneumonitis following measles-mumps-rubella vaccination of a patient with HIV infection, 1993. Morb Mortal Wkly Rep 1996; 45: 603-606.
12. Henning KJ, White MH, Sepkowitz KA, Armstrong D. A national survey of immunization practices following allogeneic bone marrow transplantation. JAMA 1997; 277: 1148-1151.
13. Shaw PJ, Bleakley M, Burgess M. Safety of early immunization against measles/mumps/rubella after bone marrow transplantation (letter). Blood 2002; 99: 3486.
14. Pauksen K, Linde A, Lonnerholm G et al. Influence of the specific T cell response on seroconversion after measles vaccination in autologous bone marrow transplant patients. Bone Marrow Transplant 1996; 18: 969-973.